Increased mortality in hemodialysis patients having specific antibodies to the platelet factor 4-heparin complex

Kidney International

Volumn 73, Issue 2, 2008, Pages 213-219

  Carrier, M ^a   Rodger, M A ^a,b   Fergusson, D ^b   Doucette, S ^b   Kovacs, M J ^c   Moore, J ^d   Kelton, J G ^d   Knoll, G A ^a,b,e  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Mortality; Mortality risk

Indexed keywords

HEPARIN; IMMUNOGLOBULIN G; THROMBOCYTE FACTOR 4;

ADULT; ANTIBODY PRODUCTION; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SCREENING; SEROTONIN RELEASE;

EID: 37549048977     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002631     Document Type: Article

References (34)

1. Vun CM, Evans S, Chesterman CN. Anti-PF4-heparin immunoglobulin G is the major class of heparin-induced thrombocytopenia antibody: findings of an enzyme-linked immunofiltration assay using membrane-bound hPF4-heparin. Br J Haematol 2001; 112: 69-75.
2. Mureebe L, Silver D. Heparin-induced thrombocytopenia: pathophysiology and management. Vasc Endovascular Surg 2002; 36: 163-170.
3. Chong BH, Pitney WR, Castaldi PA. Heparin-induced thrombocytopenia: association of thrombotic complications with heparin-dependent IgG antibody that induces thromboxane synthesis in platelet aggregation. Lancet 1982; 2: 1246-1249.
4. Wanner C, Zimmermann J, Quaschning T, Galle J. Inflammation, dyslipidemia and vascular risk factors in hemodialysis patients. Kidney Int Suppl 1997; 62: S53-S55.
5. London GM, Marchais SJ, Guerin AP et al. Inflammation, arteriosclerosis, and cardiovascular therapy in hemodialysis patients. Kidney Int Suppl 2003; 84: S88-S93.
6. Boon DM, van Vliet HH, Zietse R, Kappers-Klunne MC. The presence of antibodies against a PF4-heparin complex in patients on haemodialysis. Thromb Haemost 1996; 76: 480.
7. Sitter T, Spannagl M, Banas B, Schiffl H. Prevalence of heparin-induced PF4-heparin antibodies in hemodialysis patients. Nephron 1998; 79: 245-246.
8. Greinacher A, Zinn S, Wizemann SZ, Birk UW. Heparin-induced antibodies as a risk factor for thromboembolism and hemorrhage in patients undergoing chronic haemodialysis. Lancet 1996; 348: 764.
9. Luzzatto G, Bertoli M, Cella G et al. Platelet count, anti-heparin/platelet factor 4 antibodies and tissue factor pathway inhibitor plasma antigen level in chronic dialysis. Thromb Res 1998; 89: 115-122.
10. Yu A, Jacobson SH, Bygden A, Egberg N. The presence of heparin-platelet factor 4 antibodies as a marker of hypercoagulability during hemodialysis. Clin Chem Lab Med 2002; 40: 21-26.
11. Mattioli AV, Bonetti L, Sternieri S, Mattioli G. Heparin-induced thrombocytopenia in patients treated with unfractionated heparin: prevalence of thrombosis in a 1 year follow-up. Ital Heart J 2000; 1: 39-42.
12. Nakamoto H, Shimada Y, Kanno T et al. Role of platelet factor 4-heparin complex antibody (HIT antibody) in the pathogenesis of thrombotic episodes in patients on hemodialysis. Hemodial Int 2005; 9: S2-S7.
13. Mureebe L, Coats RD, Silliman WR et al. Heparin-associated antiplatelet antibodies increase morbidity and mortality in hemodialysis patients. Surgery 2004; 136: 848-853.
14. Pena de la Vega L, Miller RS, Benda MM et al. Association of heparindependent antibodies and adverse outcomes in hemodialysis patients: a Population-Based Study. Mayo Clin Proc 2005; 80: 995-1000.
15. Warkentin TE, Levine MN, Hirsh J et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-1336.
16. Chang JJY, Parikh CR. When heparin causes thrombosis: significance, recognition, and management of heparin-induced thrombocytopenia in dialysis patients. Semin Dial 2006; 19: 297-304.
17. Leehey DJ, Kanak RJ, Messmore HL et al. Heparin-associated thrombocytopenia in maintenance hemodialysis patients. Int J Artif Organs 1987; 10: 390-392.
18. Sonawane S, Kasbekar N, Berns JS. The safety of heparins in end-stage renal disease. Semin Dial 2006; 19: 305-310.
19. Dager WE, White RH. Use of lepirudin in patients with heparin-induced thrombocytopenia and renal failure requiring hemodialysis. Ann Pharmacother 2001; 35: 885-890.
20. Nowak G, Bucha E, Brauns I, Czerwinski R. Anticoagulation with r-hirudin in regular haemodialysis with heparin-induced thrombocytopenia (HIT II). The first long-term application of r-hirudin in a haemodialysis patient [comment]. Wien Klin Wochenschr 1997; 109: 354-358.
21. Reedy BV, Grossman EJ, Trevino SA et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy. Ann Pharmacother 2005; 39: 1601-1605.
22. Tang IY, Cox DS, Patel K et al. Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia. Ann Pharmacother 2005; 39: 231-236.
23. Haase M, Bellomo R, Rocktaeschel J et al. Use of fondaparinux (ARIXTRA) in a dialysis patient with symptomatic heparin-induced thrombocytopaenia type II. Nephrol Dial Transplant 2005; 20: 444-446.
24. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001; 344: 1286-1292.
25. Stenvinkel P. Inflammation in end-stage renal disease: the hidden enemy. Nephrology 2006; 11: 36-41.
26. Knoll GA, Wells PS, Young D et al. Thrombophilia and the risk of hemodialysis vascular access thrombosis. J Am Soc Nephol 2005; 16: 1108-1114.
27. Carrier M, Knoll GA, Fergusson D et al. The prevalence of antibodies to the platelet factor 4-heparin complex and association with venous access thrombosis in patients on chronic hemodialysis. Thromb Res 2007; 120: 215-220.
28. Warkentin TE, Sheppard JI. No significant improvement in diagnostic specificity of an anti-PF4/polyanion immunoassay with use of high heparin confirmatory procedure. J Thromb Haemost 2006; 4: 281-282.
29. Warkentin TE, Sheppard JI, Moore JC et al. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? J Lab Med 2005; 146: 341-346.
30. Warkentin TE, Sheppard JAL. Testing for heparin-induced thrombocytopenia antibodies. Transfus Med Rev 2006; 20: 259-272.
31. Warkentin TE, Sheppard JA, Horsewood P et al. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000; 96: 1703-1708.
32. Horsewood P, Warkentin TE, Hayward CPM, Kelton JG. The epitope specificity of heparin-induced thrombocytopenia. Br J Haematol 1996; 95: 161-167.
33. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986; 67: 27-30.
34. Warkentin TE, Hayward CPM, Smith CA et al. Determinant of donor platelet variability when testing for heparin-induced thrombocytopenia. J Clin Med 1992; 120: 371-379.